Jul 10 |
Prelude and MSD partner to trial PRT3789 and Keytruda combination
|
Jul 9 |
Prelude, Merck strike clinical trial collaboration and supply pact
|
Jul 9 |
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
|
Jun 20 |
Barclays cuts Prelude to underweight, cites lack of near-term catalysts
|
Jun 20 |
Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls
|
Jun 3 |
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
|
May 30 |
Prelude Therapeutics files for $400M mixed securities shelf
|
May 9 |
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
|
May 7 |
Prelude Therapeutics GAAP EPS of -$0.42
|
May 7 |
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|